Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 26, 2023; 11(12): 2832-2838
Published online Apr 26, 2023. doi: 10.12998/wjcc.v11.i12.2832
Furazolidone-induced pulmonary toxicity in Helicobacter pylori infection: Two case reports
Yao Ye, Zi-Ling Shi, Zhuo-Chao Ren, Yi-Lan Sun
Yao Ye, Zi-Ling Shi, Zhuo-Chao Ren, Yi-Lan Sun, Geriatric Medicine Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
Zi-Ling Shi, Graduate School of Clinical Medicine, Bengbu Medical College, Bengbu 233000, Anhui Province, China
Author contributions: Ye Y, Shi ZL, Ren ZC, and Sun YL conceptualized and designed the study, collected and analyzed data, they have read and approved the final manuscript; Ye Y and Shi ZL contributed to writing-original draft preparation; Ye Y, Ren ZC and Sun YL contributed to writing-review and editing, treatment of the patient; Sun YL contributed to supervision.
Informed consent statement: Written informed consent was obtained from the patients for the publication of this case report.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi-Lan Sun, PhD, Chief Physician, Doctor, Geriatric Medicine Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, No. 158 Shangtang Street, Gongshu District, Hangzhou 310014, Zhejiang Province, China. sunylhz1974@126.com
Received: December 30, 2022
Peer-review started: December 30, 2022
First decision: February 2, 2023
Revised: February 7, 2023
Accepted: March 30, 2023
Article in press: March 30, 2023
Published online: April 26, 2023
Processing time: 116 Days and 14.7 Hours
Core Tip

Core Tip: Furazolidone should be used as a treatment option for Helicobacter pylori (H. pylori) eradication in China because of high antibiotic resistance. We present two cases of furazolidone-induced pulmonary hypersensitivity determined by the Naranjo Adverse Drug Reaction Probability Scale score. Clinicians should be aware of the adverse effects of furazolidone, especially as it is widely used in the treatment of H. pylori infection in China.